This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Prasad, A. Articles by Quyyumi, A. A. Search for Related Content PubMed PubMed Citation Articles by Prasad, A. Articles by Quyyumi, A. A.

Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis

Abhiram Prasad, MD, MRCP^*, Julian P. J. Halcox, MA, MRCP^*, Myron A. Waclawiw, PhD and Arshed A. Quyyumi, MD, FRCP, FACC^*

^* Cardiology Branch, Bethesda, Maryland, USA
Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA

View larger version (16K): [in a new window]   Figure 1 Percent change in epicardial diameter (flow-mediated dilation) (top) and coronary vascular resistance (bottom) during adenosine, before (control) and after losartan.

View larger version (14K): [in a new window]   Figure 2 Percent change in epicardial diameter (top) and coronary vascular resistance (bottom) during cold pressor testing, before (control) and after losartan.

View larger version (14K): [in a new window]   Figure 3 Percent change in epicardial diameter (top) and coronary vascular resistance (bottom) during exercise, before (control) and after losartan.